Ken Griffin Natera, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Natera, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 60,700 shares of NTRA stock, worth $7.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,700

Previous 55,900 8.59%

Holding current value

$7.57 Million

Previous $5.11 Million 28.58%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$85.28 - $112.6 $60.2 Million - $79.5 Million	706,288 Added 30.16%	3,047,899 $330 Million
Q1 2024 May 15, 2024	BUY	$59.21 - $92.9 $40.2 Million - $63 Million	678,267 Added 40.78%	2,341,611 $214 Million
Q4 2023 Feb 14, 2024	BUY	$37.55 - $62.64 $62.3 Million - $104 Million	1,659,765 Added 46375.1%	1,663,344 $104 Million
Q3 2023 Nov 14, 2023	SELL	$43.4 - $62.52 $37.9 Million - $54.5 Million	-872,328 Reduced 99.59%	3,579 $158,000
Q2 2023 Aug 14, 2023	SELL	$47.08 - $55.16 $91.9 Million - $108 Million	-1,951,769 Reduced 69.02%	875,907 $42.6 Million
Q1 2023 May 15, 2023	SELL	$36.57 - $58.29 $8.09 Million - $12.9 Million	-221,272 Reduced 7.26%	2,827,676 $157 Million
Q4 2022 Feb 14, 2023	BUY	$34.17 - $47.91 $30.2 Million - $42.4 Million	884,865 Added 40.89%	3,048,948 $122 Million
Q3 2022 Nov 14, 2022	BUY	$36.93 - $56.68 $19.1 Million - $29.3 Million	517,051 Added 31.39%	2,164,083 $94.8 Million
Q2 2022 Aug 15, 2022	BUY	$28.13 - $44.54 $3.42 Million - $5.41 Million	121,511 Added 7.97%	1,647,032 $58.4 Million
Q1 2022 May 16, 2022	BUY	$30.32 - $91.33 $26.1 Million - $78.7 Million	862,070 Added 129.94%	1,525,521 $62.1 Million
Q4 2021 Feb 14, 2022	BUY	$86.26 - $119.0 $5.72 Million - $7.9 Million	66,347 Added 11.11%	663,451 $62 Million
Q3 2021 Nov 15, 2021	SELL	$100.17 - $126.36 $34.4 Million - $43.4 Million	-343,803 Reduced 36.54%	597,104 $66.5 Million
Q2 2021 Aug 16, 2021	BUY	$86.05 - $119.72 $24.7 Million - $34.4 Million	287,582 Added 44.02%	940,907 $107 Million
Q1 2021 May 17, 2021	BUY	$91.47 - $124.36 $24.7 Million - $33.5 Million	269,763 Added 70.33%	653,325 $66.3 Million
Q4 2020 Feb 16, 2021	BUY	$66.66 - $111.74 $9.29 Million - $15.6 Million	139,313 Added 57.04%	383,562 $38.2 Million
Q3 2020 Nov 16, 2020	BUY	$45.89 - $72.67 $10.6 Million - $16.8 Million	231,690 Added 1844.81%	244,249 $17.6 Million
Q2 2020 Aug 14, 2020	SELL	$26.36 - $49.86 $2.65 Million - $5.01 Million	-100,476 Reduced 88.89%	12,559 $626,000
Q1 2020 May 15, 2020	SELL	$17.27 - $40.17 $2.55 Million - $5.93 Million	-147,613 Reduced 56.63%	113,035 $3.38 Million
Q4 2019 Feb 14, 2020	BUY	$32.1 - $40.4 $5.82 Million - $7.32 Million	181,203 Added 228.09%	260,648 $8.78 Million
Q3 2019 Nov 14, 2019	SELL	$25.38 - $34.89 $1.59 Million - $2.19 Million	-62,738 Reduced 44.12%	79,445 $2.61 Million
Q1 2019 May 15, 2019	SELL	$11.34 - $20.62 $1.45 Million - $2.65 Million	-128,284 Reduced 47.43%	142,183 $0
Q4 2018 Feb 14, 2019	SELL	$12.32 - $24.38 $1.28 Million - $2.54 Million	-104,225 Reduced 27.82%	270,467 $3.78 Million
Q3 2018 Nov 13, 2018	BUY	$18.82 - $28.96 $4.42 Million - $6.8 Million	234,965 Added 168.16%	374,692 $0
Q2 2018 Aug 10, 2018	BUY	$8.79 - $19.98 $349,156 - $793,645	39,722 Added 39.72%	139,727 $0
Q1 2018 May 11, 2018	SELL	$9.0 - $11.95 $115,425 - $153,258	-12,825 Reduced 11.37%	100,005 $927,000
Q4 2017 Feb 09, 2018	BUY	$8.99 - $14.31 $100,679 - $160,257	11,199 Added 11.02%	112,830 $1.01 Million
Q3 2017 Nov 09, 2017	BUY	$8.02 - $13.33 $815,080 - $1.35 Million	101,631	101,631 $1.31 Million

Others Institutions Holding NTRA

# of Institutions

509

Shares Held

120M

Call Options Held

412K

Put Options Held

270K

View Full List

About Natera, Inc.

Ticker NTRA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 96,957,400
Market Cap $12.1B
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...

More about NTRA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account